| Product Unit Size | Cost | Quantity | Stock |
|---|
VX-702 inhibits p38 MAPK, preventing p38 MAPK-dependent inflammatory cytokine release. VX-702 is in development to treat inflammation and cardiovascular diseases and currently shows mixed results in clinical trials as a potential treatment for rheumatoid arthritis. In vitro, VX-702 decreases platelet lesioning in storage without affecting platelet function.
| Cas No. | 479543-46-9 |
|---|---|
| Purity | ≥98% |
| Formula | C19H12F4N4O2 |
| Formula Wt. | 404.32 |
| IUPAC Name | 6-(N-carbamoyl-2,6-difluoroanilino)-2-(2,4-difluorophenyl)pyridine-3-carboxamide |
| Synonym | VX702 |
| Solubility | DMSO 81 mg/mL (200.34 mM) Water Insoluble Ethanol Insoluble |
| Appearance | White Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Skripchenko A, Awatefe H, Thompson-Montgomery D, et al. An inhibition of p38 mitogen activated protein kinase delays the platelet storage lesion. PLoS One. 2013 Aug 13;8(8):e70732. PMID: 23967093.
Ding C. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr Opin Investig Drugs. 2006 Nov;7(11):1020-5. PMID: 17117592.
Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem. 2005;12(25):2979-94. PMID: 16378500.